Tumor-inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. V. Synthesis and evaluation of enantiomeric [1,2-bis-(4-fluorophenyl)ethylenediamine]dichloroplatinum(II) complexes.
The enantiomeric [1,2-bis(4-fluorophenyl)ethylenediamine]dichloroplatinum(II) complexes were synthesized and tested on the hormone-sensitive human MCF7 breast cancer cell line and on the P388 leukemia of the mouse. They showed a strong and comparable activity on both tumor models.
vom Orde
H D
HD
Institut für Pharmazie, Lehrstuhl Pharmazeutische Chemie II, Sonderforschungsbereich 234 (SFB 234), Universität Regensburg, Federal Republic of Germany.
Reile
H
H
Müller
R
R
Gust
R
R
Bernhardt
G
G
Spruss
T
T
Schönenberger
H
H
Burgemeister
T
T
Mannschreck
A
A
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy*; D002945:Cisplatin / Q000627:therapeutic use; D006801:Humans; D066298:In Vitro Techniques; D007941:Leukemia P388 / Q000188:drug therapy*; D051379:Mice; D008811:Mice, Inbred DBA; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C064244:(1,2-bis(4-fluorophenyl)ethylenediamine)dichloroplatinum(II); D002945:Cisplatin